Apogee Therapeutics
Waltham, Massachusetts, United States · research · 200 employees
Apogee Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative biologic therapies for inflammatory and immunology diseases. Their focus includes conditions such as atopic dermatitis, asthma, and chronic obstructive pulmonary disease. The company aims to enhance the standard of care by creating differentiated antibody therapeutics that provide improved efficacy, op
Funding history
- Series public offering — $350.0M — Mar 2026
Recent signals
- Mar 25, 2026: Raised $350.0M in Series public offering
- Mar 24, 2026: SEC 8-K (1.01): On March 24, 2026, Apogee Therapeutics, Inc. entered into an underwriting agreement with Jefferies LLC, TD Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated, and Guggenheim Securities, LLC, to issue and sell 5,000,000 shares of common stock at a public offering price of $70.00 per share. Additionally, the Company granted the Underwriters a 30-day option to purchase up to 750,000 additional shares, which was fully exercised on March 25, 2026. The total offering aimed to raise substantial capital for the company, potentially impacting its financial position and strategic initiatives going forward.
- Jan 06, 2026: SEC 8-K (7.01): On January 6, 2026, Apogee Therapeutics, Inc. issued a press release announcing positive interim data from its Phase 1b clinical trial of zurimokibart (APG777), an anti-IL-13 antibody, aimed at treating patients with mild-to-moderate asthma. This release highlights important data on the drug's efficacy and also discusses upcoming milestones for the company in 2026. A conference call and webcast was scheduled for the same day at 8:00 a.m. Eastern Time to further elaborate on the data results. This announcement could significantly impact the company's strategic direction and investor perception, given the potential of APG777 in a competitive therapeutic area.
- Nov 18, 2024: Launched Apogee Therapeutics, Inc. announces its inaugural virtual R&D Day set for December 2, 2024.
- Sep 09, 2024: Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer
See plans & pricing → Track Apogee Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.